Aim of study | Enrollment | Phase | Status | ClinicalTrials.gov identifier |
---|---|---|---|---|
To determine if the administration of allogeneic MSCs at defined doses is safe in patients who are at high risk of developing significant AKI after undergoing on-pump cardiac surgery | 18 | Phase I | Completed | NCT00733876 |
To determine the safety and efficacy of allogeneic human MSCs in reducing the time to recover from AKI after cardiac surgery | 156 | Phase II | Terminated | NCT01602328 |
To assess the safety and tolerability of SBI-101, a biologic/device combination product using allogeneic human MSCs in subjects with AKI | 24 | Phase I | Recruiting | NCT03015623 |